Travere Therapeutics Inc Pegtibatinase in Classical Homocystinuria Phase 1/2 COMPOSE Study Results Call Transcript
Hello, ladies and gentlemen, and thank you for standing by. Welcome to the Travere Therapeutics Corporate Update Call. I would now like to turn the call over to your host, Naomi Eichenbaum, Vice President of Investor Relations. Ms. Eichenbaum, please go ahead.
Thank you, Melinda, and thank you all for joining us today. Earlier today, we issued a press release covering the positive top line results from Cohort 6 in the Phase I/II COMPOSE Study of pegtibatinase in classical homocystinuria. A copy of the release, along with the slides that we'll be reviewing on today's call, are available on our Investor Relations website. Today's call will be led by our Chief Executive Officer, Dr. Eric Dube. Joining Eric will be our SVP of Research and Development, Dr. Bill Rote; and Dr. John Ficicioglu, MD, PhD, Clinical Director of the Metabolic Disease Program at Children's Hospital of Philadelphia. Our Chief Medical Officer, Dr. Jula Inrig, will also be available during the Q&A session.
Before we begin, I'd like to remind everyone that statements made
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |